Cosmos Health guides $90M+ FY26 revenue on record Q4 outlook

Cosmos Health reaffirmed full-year 2026 revenue guidance of more than $90 million, up approximately 38%, the largest single-year revenue increase in the company's history. Preliminary nine-month 2026 revenue reached approximately $54.3 million, up 19% YoY, with Q4 implied at approximately $35.7 million, up approximately 81% from Q4 2025. U.S. e-commerce platform reported 8,940 active subscriptions as of October 19, 2026, up 42% in five days, with approximately $15 million in Q4 revenue and approximately $10.5 million in gross profit expected. Cana Laboratories' contract manufacturing pipeline grew to more than 32.7 million units, up sixfold since mid-2024, with an implied gross margin of approximately 90%. Fiscal 2029 guidance targets revenue of $200.6 million, gross profit of $71.2 million and adjusted EBITDA of $44.2 million, with the objective of becoming self-funding by 2027.

Cosmos Health reaches 6,287 active US subscriptions

Cosmos Health reported 6,287 active U.S. subscriptions as of October 14, 2026. Monthly subscription value stands at $919,945 at standard renewal pricing. 60.5% of online checkout orders included a subscription, rising to over 75% recently. Average basket depth is 2.4 product units per subscription across 12,408 lines. Company plans to extend subscription model to other brands and international markets.

Cosmos Health expects 70% gross margins; reaffirms $200.6M 2029 target

Cosmos Health reiterates 2029 revenue target of $200.6 million. Expects gross margins exceeding 70% for key proprietary brands. Distribution business currently constitutes majority of consolidated revenue. Portfolio sold in over 40 countries addressing $946 billion market.

Cosmos Health CosmoFarm Q2FY26 Results: Revenue tops $15M, hits $60M run rate

CosmoFarm delivered record Q2FY26 revenue of over $15 million, establishing an annualized run rate exceeding $60 million. Revenue has grown 4.3x under Cosmos Health ownership since 2017, achieving a CAGR of approximately 18%. A letter of intent was signed in 2026 for a network generating approximately $11.5 million in annual gross revenue. New AI-powered call center deployment and robotics investments support capacity for annualized revenue above $100 million.

Cana Labs CMO pipeline tops $20M revenue, 90% gross margin

Cana Laboratories' CMO pipeline surpassed $20 million in implied revenue. Implied gross profit exceeds $18 million with margins above 90%. Production pipeline reaches a record of more than 32.7 million units.

Cosmos Health secures 2.5 million unit Viofar contract

Cosmos Health subsidiary Cana secures five-year deal with Viofar for 2.5 million units of ROSARTIA. Annual production commitment stands at 500,000 units across four dosage strengths. Cumulative contract manufacturing orderbook rises to over 27.5 million units from 25 million. Company has invested $5.5 million in upgrading its EMA-certified Athens manufacturing facility.